IRVING, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. today announced the publication of an article in the May 2007 issue of the journal Cancer Research showing that RTA 402, the company’s Phase 2 development candidate for cancer, was highly effective in a rigorous animal model of breast cancer and that the drug inhibits signaling activity of STAT3, an important target for new cancer therapies.
